18h
Newsable Asianet News on MSNTravere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease DrugShares of Travere Therapeutics Inc. surged over 13% Tuesday afternoon, reaching their highest level since October 2022 and ...
She was diagnosed with a genetic kidney disease called reflux nephropathy which later progressed to kidney failure. "That was ...
The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...
Scientist develop new equation for detecting hyperfiltration that incorporates age but not body surface area. Read more!
The researchers tested PEITC in rats that had diabetic nephropathy. Their results showed evidence that PEITC may help repair ...
Time-in-range computed from virtual CGM data predicts retinopathy, neuropathy similarly to glycated hemoglobin data ...
Male and female patients ≥ 18 years of age with an eGFR level and biopsy-confirmed IgA nephropathy as follows: * For patients eGFR\* ≥ 45ml/min/1.73m2, a qualifying biopsy performed within the last 5 ...
19d
Hosted on MSNVertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...
Cortisone injections are commonly used to treat a variety of orthopedic conditions. People with diabetes are especially prone to side effects from cortisone injections, often experiencing a temporary ...
Tonabersat is under clinical development by Inflammx Therapeutics and currently in Phase II for Diabetic Nephropathy. According to GlobalData, Phase II drugs for Diabetic Nephropathy have a 28% phase ...
Intermittent fasting (IF) for people with diabetes has the potential benefit of improving blood glucose—and possibly reversing diabetes or going into "remission." The key is balancing these benefits ...
AROC-3 by Arrowhead Pharmaceuticals for IgA Nephropathy (Berger’s Disease): Likelihood of Approval
AROC-3 is under development for the treatment of adult patients with complement-mediated renal disease (C3 glomerulopathy [C3G] (glomerulonephritis) and IgA nephropathy [IgAN]). It acts by targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results